• Hirohiko Abe, Shinya Minatoguchi, Hiroshige Ohashi, Ichijiro Murata, Taro Minagawa, Toshio Okuma, Hitomi Yokoyama, Hisato Takatsu, Tadatake Takaya, Toshihiko Nagano, Yukio Osumi, Masao Kakami, Tatsuo Tsukamoto, Tsutomu Tanaka, Kunihiko Hiei, and Hisayoshi Fujiwara.
• Second Department of Internal Medicine, Gifu University School of Medicine, Japan.
• Hypertens. Res. 2007 Oct 1;30(10):929-35.

AbstractAngiotensin converting enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers (ARBs) are frequently used for the treatment for glomerulonephritis and diabetic nephropathy because of their albuminuria- or proteinuria-reducing effects. To many patients who are nonresponsive to monotherapy with these agents, combination therapy appears to be a good treatment option. In the present study, we examined the effects of the addition of an ARB (losartan) followed by titration upon addition and at 3 and 6 months (n=14) and the addition of an ACE-I followed by titration upon addition and at 3 and 6 months (n=20) to the drug regimen treatment protocol in type 2 diabetic patients with nephropathy for whom more than 3-month administration of an ACE-I or the combination of an ACE-I plus a conventional antihypertensive was ineffective to achieve a blood pressure (BP) of 130/80 mmHg and to reduce urinary albumin to <30 mg/day. During the 12-month treatment, addition of losartan or addition of an ACE-I to the treatment protocol reduced systolic blood pressure (SBP) by 10% and 12%, diastolic blood pressure (DBP) by 7% and 4%, and urinary albumin excretion by 38% and 20% of the baseline value, respectively. However, the effects on both BP and urinary albumin were not significantly different between the two therapies. In conclusion, addition of losartan or an ACE-I to an ongoing treatment with an ACE-I, or addition of an ACE-I to ongoing treatment with a conventional antihypertensive were equally effective at reducing the urinary albumin excretion and BP, and provided renal protection in patients with type-2 diabetic nephropathy.

39 keywords...

hide…